DMRA Stock Forecast & Price Target

Damora Therapeutics is viewed favorably because DMR-001 appears differentiated by activity across both Type 1 and Type 2 mutCALR mutations and by a projected once-monthly subcutaneous dosing profile, which could improve convenience and broaden uptake versus incumbent approaches. The company’s balance sheet is a major support, with $540.5 million in cash and equivalents at the end of 2Q26 expected to fund operations into 2H29, giving it runway through mid-2027 proof-of-concept data and potentially into early phase 3 development as early as mid-2028. Additional upside comes from DMR-002 and DMR-003 as further shots on goal, while the broader anti-mutCALR franchise could benefit from a large disease-modifying opportunity in ET and MF where current treatment options remain limited.

Damora Therapeutics is a pre-clinical biotech with no long-term debt and about $422M in end-2Q27 cash, but its valuation rests heavily on a 10% discount rate DCF and a narrow set of clinical assumptions rather than proven execution. The bearish view is driven by the risk that DMR-001’s mid-2027 Ph 1 POC readout fails to beat INCA033989 in non-Type 1 mutCALR ET or MF, or cannot confirm SC Q4W tolerability and PK at efficacy-relevant doses, while delays, safety issues, and new competitors remain credible threats. More broadly, the unmet need is real, but the market is crowded and biologically difficult, with chronic MPN adoption, endpoint uncertainty, and financing or dilution risk all weighing on the company before any clinical de-risking.